Diorasis Therapeutics (DTx), a preclinical-stage biotechnology company developing gene therapies for ophthalmic diseases, has partnered with Northway Biotech (NBT), a contract development and manufacturing organization (CDMO), to establish a scalable cGMP production process for DTx’s lead AAV-based gene therapy candidate for open angle glaucoma. As part of the collaboration, Northway Biotech will leverage its experience in biologics manufacturing to develop a robust, compliant process for pre...